JP7527273B2 - 多量体タンパク質の量および純度を決定するための方法およびクロマトグラフィーシステム - Google Patents

多量体タンパク質の量および純度を決定するための方法およびクロマトグラフィーシステム Download PDF

Info

Publication number
JP7527273B2
JP7527273B2 JP2021507759A JP2021507759A JP7527273B2 JP 7527273 B2 JP7527273 B2 JP 7527273B2 JP 2021507759 A JP2021507759 A JP 2021507759A JP 2021507759 A JP2021507759 A JP 2021507759A JP 7527273 B2 JP7527273 B2 JP 7527273B2
Authority
JP
Japan
Prior art keywords
protein
affinity matrix
antibody
fcfc
impurity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021507759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534398A5 (https=
JP2021534398A (ja
Inventor
マイケル ペローネ、
オードリー ロドリゲス、
アンドリュー タスティアン、
ハンネ バク、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2021534398A publication Critical patent/JP2021534398A/ja
Publication of JP2021534398A5 publication Critical patent/JP2021534398A5/ja
Priority to JP2024117397A priority Critical patent/JP2024156725A/ja
Application granted granted Critical
Publication of JP7527273B2 publication Critical patent/JP7527273B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation
    • G01N30/14—Preparation by elimination of some components
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/86—Signal analysis
    • G01N30/8624—Detection of slopes or peaks; baseline correction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
JP2021507759A 2018-08-17 2019-08-16 多量体タンパク質の量および純度を決定するための方法およびクロマトグラフィーシステム Active JP7527273B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024117397A JP2024156725A (ja) 2018-08-17 2024-07-23 多量体タンパク質の量および純度を決定するための方法およびクロマトグラフィーシステム

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719323P 2018-08-17 2018-08-17
US62/719,323 2018-08-17
PCT/US2019/046769 WO2020037182A1 (en) 2018-08-17 2019-08-16 Method and chromatography system for determining amount and purity of a multimeric protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024117397A Division JP2024156725A (ja) 2018-08-17 2024-07-23 多量体タンパク質の量および純度を決定するための方法およびクロマトグラフィーシステム

Publications (3)

Publication Number Publication Date
JP2021534398A JP2021534398A (ja) 2021-12-09
JP2021534398A5 JP2021534398A5 (https=) 2022-08-18
JP7527273B2 true JP7527273B2 (ja) 2024-08-02

Family

ID=67851218

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021507759A Active JP7527273B2 (ja) 2018-08-17 2019-08-16 多量体タンパク質の量および純度を決定するための方法およびクロマトグラフィーシステム
JP2024117397A Pending JP2024156725A (ja) 2018-08-17 2024-07-23 多量体タンパク質の量および純度を決定するための方法およびクロマトグラフィーシステム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024117397A Pending JP2024156725A (ja) 2018-08-17 2024-07-23 多量体タンパク質の量および純度を決定するための方法およびクロマトグラフィーシステム

Country Status (14)

Country Link
US (2) US12152056B2 (https=)
EP (1) EP3837552A1 (https=)
JP (2) JP7527273B2 (https=)
KR (2) KR102795000B1 (https=)
CN (2) CN118641770A (https=)
AU (1) AU2019322895B2 (https=)
BR (1) BR112021002724A2 (https=)
CA (1) CA3109362A1 (https=)
EA (1) EA202190459A1 (https=)
IL (2) IL325196A (https=)
MX (1) MX2021001915A (https=)
MY (1) MY207066A (https=)
SG (1) SG11202101369XA (https=)
WO (1) WO2020037182A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY207066A (en) * 2018-08-17 2025-01-28 Regeneron Pharma Method and chromatography system for determining amount and purity of a multimeric protein
WO2020252260A1 (en) * 2019-06-13 2020-12-17 Regeneron Pharmaceuticals, Inc. Methods for removing undesired components during multistage chromatographic processes
WO2022234412A1 (en) 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
WO2026075981A1 (en) * 2024-10-01 2026-04-09 Regeneron Pharmaceuticals, Inc. Methods of analyzing heterodimeric proteins

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501911A (ja) 2010-10-27 2014-01-23 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ ガードカラムを備えるクロマトグラフィーシステム
JP2015052533A (ja) 2013-09-06 2015-03-19 株式会社日立製作所 クロマトグラフィー装置およびクロマトグラフィー方法
JP2015520667A (ja) 2012-04-23 2015-07-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ クロマトグラフィー法
WO2016018740A2 (en) 2014-07-26 2016-02-04 Regeneron Pharmaceuticals, Inc. Purification platform for bispecific antibodies
WO2016164708A1 (en) 2015-04-10 2016-10-13 Adimab, Llc Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
WO2017134440A2 (en) 2016-02-05 2017-08-10 Dr Philip C JONES Heterodimers and purification thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
US7691645B2 (en) * 2001-01-09 2010-04-06 Agilent Technologies, Inc. Immunosubtraction method
SG149759A1 (en) * 2007-07-10 2009-02-27 Millipore Corp Media for affinity chromatography
SG177202A1 (en) * 2008-09-15 2012-01-30 Emd Millipore Corp Methods for quantifying protein leakage from protein based affinity chromatography resins
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
US20130248451A1 (en) * 2010-12-03 2013-09-26 Ge Healthcare Bio-Sciences Ab System and process for biopolymer chromatography
EP2500073A1 (en) 2011-03-17 2012-09-19 ChromaCon AG Method for identification and purification of multi-specific polypeptides
KR20150008171A (ko) 2012-05-10 2015-01-21 자임워크스 인코포레이티드 단일군 일가 항체 구조물 및 그의 용도
AU2014226126B2 (en) * 2013-03-08 2019-02-14 Genzyme Corporation Continuous purification of therapeutic proteins
JP2016538275A (ja) 2013-11-04 2016-12-08 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
WO2016149088A1 (en) * 2015-03-13 2016-09-22 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
MY207066A (en) * 2018-08-17 2025-01-28 Regeneron Pharma Method and chromatography system for determining amount and purity of a multimeric protein

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501911A (ja) 2010-10-27 2014-01-23 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ ガードカラムを備えるクロマトグラフィーシステム
JP2015520667A (ja) 2012-04-23 2015-07-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ クロマトグラフィー法
JP2015052533A (ja) 2013-09-06 2015-03-19 株式会社日立製作所 クロマトグラフィー装置およびクロマトグラフィー方法
WO2016018740A2 (en) 2014-07-26 2016-02-04 Regeneron Pharmaceuticals, Inc. Purification platform for bispecific antibodies
JP2017524740A (ja) 2014-07-26 2017-08-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗体のための精製プラットフォーム
WO2016164708A1 (en) 2015-04-10 2016-10-13 Adimab, Llc Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
JP2018512431A (ja) 2015-04-10 2018-05-17 アディマブ， エルエルシー 親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法
WO2017134440A2 (en) 2016-02-05 2017-08-10 Dr Philip C JONES Heterodimers and purification thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
TUSTIAN, A. et al.，Development of a novel affinity chromatography resin for platform purification of bispecific antibodies with modified protein a binding avidity，Biotechnol Prog，2018年05月08日，Vol.34, No.3，p.650-658，doi: 10.1002/btpr.2622
サーモフィッシャーサイエンティフィック，アフィニティ精製における結合・溶出条件の最適化まとめ，分子生物学実験関連，2016年05月30日，[online], [令和５年７月３１日検索], インターネット＜URL： https://www.thermofisher.com/blog/learning-at-the-bench/optimization-of-affinity-purification/＞
ベリタス，Dynabeads Protein A または Dynabeads Ptotein Gを用いた免疫沈降で、低pH条件で溶出した時、解離する部位はどこでしょうか？，技術資料 FAQ，2004年，[online], [令和５年７月３１日検索], インターネット＜URL： https://www.veritastk.co.jp/products/reference/faq/Faq2_663.html＞

Also Published As

Publication number Publication date
EP3837552A1 (en) 2021-06-23
AU2019322895A1 (en) 2021-03-11
US12152056B2 (en) 2024-11-26
JP2024156725A (ja) 2024-11-06
KR102795000B1 (ko) 2025-04-15
KR20250053213A (ko) 2025-04-21
IL325196A (en) 2026-02-01
MX2021001915A (es) 2021-05-31
KR20210045413A (ko) 2021-04-26
CN112771379A (zh) 2021-05-07
EA202190459A1 (ru) 2021-07-21
CN112771379B (zh) 2024-07-02
BR112021002724A2 (pt) 2021-07-20
IL280764B1 (en) 2026-01-01
US20210382065A1 (en) 2021-12-09
JP2021534398A (ja) 2021-12-09
SG11202101369XA (en) 2021-03-30
WO2020037182A1 (en) 2020-02-20
US20200055894A1 (en) 2020-02-20
AU2019322895B2 (en) 2026-03-19
CA3109362A1 (en) 2020-02-20
MY207066A (en) 2025-01-28
IL280764A (en) 2021-04-29
CN118641770A (zh) 2024-09-13

Similar Documents

Publication Publication Date Title
JP2024156725A (ja) 多量体タンパク質の量および純度を決定するための方法およびクロマトグラフィーシステム
JP6702967B2 (ja) 二重特異性抗体のための精製プラットフォーム
JP7137663B2 (ja) 多量体タンパク質の純度の決定
Ghose et al. Antibody variable region interactions with Protein A: implications for the development of generic purification processes
US11649262B2 (en) Method for promoting efficiency of purification of Fc region-containing polypeptide
JP2018184487A (ja) 抗体を精製する方法
JP2021152544A6 (ja) 多量体タンパク質の純度の決定
BRPI0611600B1 (pt) Método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
KR20180034500A (ko) 친화성 크로마토그래피에서의 숙주 세포 단백질 감소 방법
WO2020172658A1 (en) Methods of isolating a protein
Amaral et al. Rado� evic K, Rao E. Engineered Technologies and Bioanalysis of multispecific antibody formats
EP3337817B1 (en) Method for the reduction of host cell proteins in affinity chromatography
EA050781B1 (ru) Способ и хроматографическая система для определения количества и чистоты мультимерного белка
EA047453B1 (ru) Способ и хроматографическая система для определения количества и чистоты мультимерного белка
JP7769633B2 (ja) 多重特異性分子の形成を監視するための逆相高速液体クロマトグラフィ（ｒｐ－ｈｐｌｃ）のためのシステム、材料、及び方法
EA045004B1 (ru) Способы удаления нежелательных компонентов в многостадийных хроматографических процессах
HK1252480B (en) Multimeric protein purity determination
BR112017001443B1 (pt) Método para fabricação de uma proteína

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220809

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240625

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240723

R150 Certificate of patent or registration of utility model

Ref document number: 7527273

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150